Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Next Previous
Trial Profile

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opakalim (Primary)
  • Indications Bipolar disorders; Epilepsy; Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms RISE-2

Most Recent Events

  • 02 Mar 2026 According to Biohaven Therapeutics media release, pivotal topline results are expected in the second half of 2026.
  • 12 May 2025 According to Biohaven Therapeutics media release, pivotal topline results expected in 1H 2026.
  • 13 Apr 2024 According to Biohaven Therapeutics media release, data from the study will be presented as both oral and poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top